Evidence map›Paper›PMID 40143517›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Utilizing Two Electrokinetic Techniques on a Single Device for Detection of Extracellular Vesicle-Associated Protease Activity.

Ella Stimson, Delaney Shea, Michelle M Gomes, Srivathsan Ranganathan, Sarah Mitchell, Jason Ware, Randall Armstrong, Christian Ross, Michael Heller, Stuart D Ibsen

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ella StimsonCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0002-3159-2585
Delaney SheaCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0001-8180-3937
Michelle M GomesCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0003-4809-2664
Srivathsan RanganathanCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0003-2001-607X
Sarah MitchellCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0003-3110-768X
Jason WareCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0002-5530-5843
Randall ArmstrongCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0009-0006-7547-0770
Christian RossCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0009-0001-7076-9144
Michael HellerDepartment of NanoEngineering, University of California San Diego, San Diego, CA, 92093, USA.ORCID 0000-0001-6436-0337
Stuart D IbsenCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0001-8619-3832

Funding

Distinguishing Pancreatic Cancer from Benign Pancreatic Disease using Nanoparticle-based BiomarkersR37CA258787 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Stuart Duncan Ibsen · 2022 to 2026
$2.3M
Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University Exploratory 2022-1331NCI NIH HHS R37 CA258787NCI NIH HHS R37CA258787
6 · The paper itself

Abstract

Protease activity is an emerging biomarker for cancer detection as activity levels are often increased in tumor tissue compared to healthy tissue. Of particular interest is the activity of proteases carried by extracellular vesicle (EV) nanoparticles which are oversecreted by tumors into circulation. Current methods to analyze the activity of proteases bound to EVs require complex multi-instrument sample processing to separate EVs from plasma to quantify protease activity. This makes EV-based protease activity detection a challenge for diagnostic or point-of-care applications. Here, a method is reported that manipulates EV nanoparticles and charged molecular byproducts from protease activity using two different electrokinetic phenomena generated by a single electrode microarray within a microfluidic channel. Dielectrophoresis is first generated to recover EVs carrying active trypsin-like proteases from human plasma followed by electrophoresis for subsequent analysis of peptide cleavage products indicating protease activity. This method demonstrates signal amplification through protease catalytic activity in combination with concentrating mechanisms of dielectrophoresis and electrophoresis. Using this approach, a significant difference in protease activity is observed between patients with pancreatic cancer and benign cysts. This demonstrates dual-electrokinetic chip-based technology as a useful tool to manipulate different sized and charged analytes in a single device enabling future clinical translation of EV-based protease diagnostics.

Indexed as

Extracellular VesiclesPeptide HydrolasesElectrophoresisHumansPeptide Hydrolasesdielectrophoresiselectrophoresisextracellular vesicle nanoparticlesmicroelectrode arrayprotease activity

Identifiers

PMID40143517
PMCPMC12177847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.